The relationship between prostate volume and prostate-specific antigen variability: Data from the Baltimore Longitudinal Study of Aging and the Johns Hopkins Active Surveillance Program

John H. Nichols, Stacy Loeb, E. Jeffrey Metter, Luigi Ferrucci, H Ballentine Carter

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: • To clarify the relationship between serial prostate-specific antigen (PSA) variability and prostate volume in both cancer-free participants from the Baltimore Longitudinal Study of Aging (BLSA) and patients with low-risk prostate cancer from the Johns Hopkins Active Surveillance Program (AS). MATERIALS AND METHODS: • In all, 287 men from the BLSA and 131 patients from the AS were included in the analysis, all with at least two PSA measurements and concurrent prostate volume measurements. • PSA variability was calculated in ng/mL per year, and a linear mixed-effects model was used to determine the relative effects of prostate volume, baseline PSA and age on PSA change over time. RESULTS: • In a model with prostate volume, age and baseline PSA, there was no significant relationship between prostate volume and PSA variability (BLSA, P = 0.57; AS, P = 0.49). • Only baseline PSA showed a significant relationship to PSA yearly variability (PSAYV) (P <0.001). Specifically, a one unit higher baseline PSA (ng/mL) corresponded on average to 0.09 and 0.06 ng/mL per year higher PSAYV in the BLSA and AS populations, respectively. CONCLUSIONS: • The results of the present study suggest that the primary driver of PSA variability is the baseline PSA level, rather than prostate volume. • Clinicians might consider the baseline PSA level to help predict the expected variability in serial PSA measurements.

Original languageEnglish (US)
Pages (from-to)1304-1308
Number of pages5
JournalBJU International
Volume109
Issue number9
DOIs
StatePublished - May 2012

Fingerprint

Baltimore
Prostate-Specific Antigen
Longitudinal Studies
Prostate
Population Surveillance
Population Control

Keywords

  • Prostate volume
  • PSA
  • PSA variability

ASJC Scopus subject areas

  • Urology

Cite this

The relationship between prostate volume and prostate-specific antigen variability : Data from the Baltimore Longitudinal Study of Aging and the Johns Hopkins Active Surveillance Program. / Nichols, John H.; Loeb, Stacy; Metter, E. Jeffrey; Ferrucci, Luigi; Carter, H Ballentine.

In: BJU International, Vol. 109, No. 9, 05.2012, p. 1304-1308.

Research output: Contribution to journalArticle

@article{103ef863b091483a94a4f9e1f2ddbb0c,
title = "The relationship between prostate volume and prostate-specific antigen variability: Data from the Baltimore Longitudinal Study of Aging and the Johns Hopkins Active Surveillance Program",
abstract = "OBJECTIVE: • To clarify the relationship between serial prostate-specific antigen (PSA) variability and prostate volume in both cancer-free participants from the Baltimore Longitudinal Study of Aging (BLSA) and patients with low-risk prostate cancer from the Johns Hopkins Active Surveillance Program (AS). MATERIALS AND METHODS: • In all, 287 men from the BLSA and 131 patients from the AS were included in the analysis, all with at least two PSA measurements and concurrent prostate volume measurements. • PSA variability was calculated in ng/mL per year, and a linear mixed-effects model was used to determine the relative effects of prostate volume, baseline PSA and age on PSA change over time. RESULTS: • In a model with prostate volume, age and baseline PSA, there was no significant relationship between prostate volume and PSA variability (BLSA, P = 0.57; AS, P = 0.49). • Only baseline PSA showed a significant relationship to PSA yearly variability (PSAYV) (P <0.001). Specifically, a one unit higher baseline PSA (ng/mL) corresponded on average to 0.09 and 0.06 ng/mL per year higher PSAYV in the BLSA and AS populations, respectively. CONCLUSIONS: • The results of the present study suggest that the primary driver of PSA variability is the baseline PSA level, rather than prostate volume. • Clinicians might consider the baseline PSA level to help predict the expected variability in serial PSA measurements.",
keywords = "Prostate volume, PSA, PSA variability",
author = "Nichols, {John H.} and Stacy Loeb and Metter, {E. Jeffrey} and Luigi Ferrucci and Carter, {H Ballentine}",
year = "2012",
month = "5",
doi = "10.1111/j.1464-410X.2011.10663.x",
language = "English (US)",
volume = "109",
pages = "1304--1308",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - The relationship between prostate volume and prostate-specific antigen variability

T2 - Data from the Baltimore Longitudinal Study of Aging and the Johns Hopkins Active Surveillance Program

AU - Nichols, John H.

AU - Loeb, Stacy

AU - Metter, E. Jeffrey

AU - Ferrucci, Luigi

AU - Carter, H Ballentine

PY - 2012/5

Y1 - 2012/5

N2 - OBJECTIVE: • To clarify the relationship between serial prostate-specific antigen (PSA) variability and prostate volume in both cancer-free participants from the Baltimore Longitudinal Study of Aging (BLSA) and patients with low-risk prostate cancer from the Johns Hopkins Active Surveillance Program (AS). MATERIALS AND METHODS: • In all, 287 men from the BLSA and 131 patients from the AS were included in the analysis, all with at least two PSA measurements and concurrent prostate volume measurements. • PSA variability was calculated in ng/mL per year, and a linear mixed-effects model was used to determine the relative effects of prostate volume, baseline PSA and age on PSA change over time. RESULTS: • In a model with prostate volume, age and baseline PSA, there was no significant relationship between prostate volume and PSA variability (BLSA, P = 0.57; AS, P = 0.49). • Only baseline PSA showed a significant relationship to PSA yearly variability (PSAYV) (P <0.001). Specifically, a one unit higher baseline PSA (ng/mL) corresponded on average to 0.09 and 0.06 ng/mL per year higher PSAYV in the BLSA and AS populations, respectively. CONCLUSIONS: • The results of the present study suggest that the primary driver of PSA variability is the baseline PSA level, rather than prostate volume. • Clinicians might consider the baseline PSA level to help predict the expected variability in serial PSA measurements.

AB - OBJECTIVE: • To clarify the relationship between serial prostate-specific antigen (PSA) variability and prostate volume in both cancer-free participants from the Baltimore Longitudinal Study of Aging (BLSA) and patients with low-risk prostate cancer from the Johns Hopkins Active Surveillance Program (AS). MATERIALS AND METHODS: • In all, 287 men from the BLSA and 131 patients from the AS were included in the analysis, all with at least two PSA measurements and concurrent prostate volume measurements. • PSA variability was calculated in ng/mL per year, and a linear mixed-effects model was used to determine the relative effects of prostate volume, baseline PSA and age on PSA change over time. RESULTS: • In a model with prostate volume, age and baseline PSA, there was no significant relationship between prostate volume and PSA variability (BLSA, P = 0.57; AS, P = 0.49). • Only baseline PSA showed a significant relationship to PSA yearly variability (PSAYV) (P <0.001). Specifically, a one unit higher baseline PSA (ng/mL) corresponded on average to 0.09 and 0.06 ng/mL per year higher PSAYV in the BLSA and AS populations, respectively. CONCLUSIONS: • The results of the present study suggest that the primary driver of PSA variability is the baseline PSA level, rather than prostate volume. • Clinicians might consider the baseline PSA level to help predict the expected variability in serial PSA measurements.

KW - Prostate volume

KW - PSA

KW - PSA variability

UR - http://www.scopus.com/inward/record.url?scp=84859830101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859830101&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2011.10663.x

DO - 10.1111/j.1464-410X.2011.10663.x

M3 - Article

C2 - 22093443

AN - SCOPUS:84859830101

VL - 109

SP - 1304

EP - 1308

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 9

ER -